DOCSLIB.ORG

Beacon Carrier Screening Detecting 400+ Conditions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Beacon Carrier Screening Detecting 400+ Conditions COVERAGE ~99% at 20x DELETION / DUPLICATION ≥ 2 exons TURNAROUND TIME 2 weeks* ACOG/ Expanded Focus Expanded Condition Gene Inheritance ACMG Plus (30 genes†) (401 genes†) (6 genes†) (410 genes†) Alpha thalassemia HBA1/HBA2 AR ü ü ü ü Cystic fibrosis CFTR AR ü ü ü ü Fragile X syndrome FMR1 XL ü ü ü ü Sickle cell disease; Beta thalassemia HBB AR ü ü ü ü Spinal muscular atrophy SMN1 AR ü ü ü ü Bloom syndrome BLM AR - ü ü ü Canavan disease ASPA AR - ü ü ü Congenital disorder of glycosylation type 1a PMM2 AR - ü ü ü ELP1 Familial dysautonomia AR - ü ü ü (IKBKAP) Fanconi anemia group C FANCC AR - ü ü ü Galactosemia GALT AR - ü ü ü Gaucher disease GBA AR - ü ü ü Glycogen storage disease, type 1a G6PC AR - ü ü ü Niemann-Pick disease, type A/B SMPD1 AR - ü ü ü Polycystic kidney disease, PKHD1-related PKHD1 AR - ü ü ü Smith-Lemli-Opitz syndrome DHCR7 AR - ü ü ü Tay-Sachs disease HEXA AR - ü ü ü Tyrosinemia, type 1 FAH AR - ü ü ü Citrullinemia ASS1 AR - ü ü ü Duchenne muscular dystrophy DMD XL - ü ü ü Isovaleric acidemia IVD AR - ü ü ü Medium-chain acyl-CoA dehydrogenase ACADM AR ü ü ü (MCAD) deficiency - Methylmalonic aciduria and homocystinuria, MMACHC AR ü ü ü cblC type - Mucopolysaccharidosis, type I (Hurler syndrome) IDUA AR - ü ü ü Neuronal ceroid lipofuscinosis, CLN3-related CLN3 AR - ü ü ü Phenylalanine hydroxylase deficiency PAH AR ü ü ü (Phenylketonuria) - Pompe disease GAA AR - ü ü ü Rhizomelic chondrodysplasia punctata, type 1 PEX7 AR - ü ü ü Zellweger syndrome, PEX1-related PEX1 AR - ü ü ü * Turnaround time may vary if specimen requires additional confirmatory testing. Please contact the laboratory for additional details. † This gene count reflects testing for female patients. Male patients will not be screened for X-linked conditions. ‡ Please visit our website for ethnicity-specific analytical detection rates. 4978 Santa Anita Ave, Suite 205, Temple City, CA 91780 | www.FulgentGenetics.com | [email protected] | P +1 626.350.0537 | F +1 626.454.1667 2019 © Fulgent Genetics. All Rights Reserved. D#FLY-Beacon_Genes_Conds_v2 1 ACOG/ Expanded Focus Expanded Condition Gene Inheritance ACMG Plus (30 genes†) (401 genes†) (6 genes†) (410 genes†) Abetalipoproteinemia MTTP AR - - ü ü Alport syndrome, COL4A3-related COL4A3 AR - - ü ü Arthrogryposis, mental retardation, and seizures SLC35A3 AR - - ü ü Bardet-Biedl syndrome 2; Retinitis Pigmentosa 74 BBS2 AR - - ü ü Carnitine palmitoyltransferase II deficiency CPT2 AR - - ü ü Congenital amegakaryocytic thrombocytopenia MPL AR - - ü ü Dihydrolipoamide dehydrogenase deficiency DLD AR - - ü ü Dyskeratosis congenita type 5 RTEL1 AR - - ü ü Ehlers-Danlos syndrome, Dermatosparaxis ADAMTS2 AR ü ü type VIIC - - Factor XI deficiency F11 AR - - ü ü Familial hyperinsulinism, ABCC8-related ABCC8 AR - - ü ü Joubert syndrome 2; Meckel syndrome 2 TMEM216 AR - - ü ü Maple syrup urine disease type Ia BCKDHA AR - - ü ü Maple syrup urine disease type Ib BCKDHB AR - - ü ü Mucolipidosis IV MCOLN1 AR - - ü ü Multiple sulfatase deficiency SUMF1 AR - - ü ü Muscular dystrophy-dystroglycanopathy, FKTN- FKTN AR ü ü related; Fukuyama congenital muscular dystrophy - - Nemaline myopathy NEB AR - - ü ü Non-syndromic hearing loss, PCDH15-related; PCDH15 AR / Digenic ü ü Usher syndrome, type 1F - - Phosphoglycerate dehydrogenase deficiency PHGDH AR - - ü ü Retinitis pigmentosa 59 DHDDS AR - - ü ü Usher syndrome, type 3A CLRN1 AR - - ü ü Wilson disease ATP7B AR - - ü ü Zellweger syndrome, PEX2-related PEX2 AR - - ü ü 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency HMGCL AR - - ü ü 3-Ketothiolase deficiency ACAT1 AR - - ü ü 3-Methylcrotonyl-CoA carboxylase 1 deficiency MCCC1 AR ü ü (3-MCC deficiency) - - 3-Methylcrotonyl-CoA carboxylase 2 deficiency MCCC2 AR ü ü (3-MCC deficiency) - - Achondrogenesis, type IB; Atelosteogenesis II; Diastrophic dysplasia; Multiple epiphyseal SLC26A2 AR - - ü ü dysplasia Achromatopsia CNGB3 AR - - ü ü Acrodermatitis enteropathica SLC39A4 AR - - ü ü Acyl-CoA dehydrogenase-9 (ACAD9) Deficiency ACAD9 AR - - ü ü Adenosine deaminase deficiency ADA AR - - ü ü Adrenoleukodystrophy, X-linked ABCD1 XL - - ü ü Aicardi-Goutieres syndrome SAMHD1 AR - - ü ü Alkaptonuria HGD AR - - ü ü Alpha thalassemia X-linked intellectual ATRX XL ü ü disability syndrome - - * Turnaround time may vary if specimen requires additional confirmatory testing. Please contact the laboratory for additional details. † This gene count reflects testing for female patients. Male patients will not be screened for X-linked conditions. ‡ Please visit our website for ethnicity-specific analytical detection rates. 4978 Santa Anita Ave, Suite 205, Temple City, CA 91780 | www.FulgentGenetics.com | [email protected] | P +1 626.350.0537 | F +1 626.454.1667 2019 © Fulgent Genetics. All Rights Reserved. D#FLY-Beacon_Genes_Conds_v2 2 ACOG/ Expanded Focus Expanded Condition Gene Inheritance ACMG Plus (30 genes†) (401 genes†) (6 genes†) (410 genes†) Alpha-mannosidosis MAN2B1 AR - - ü ü Alport syndrome, COL4A4-related COL4A4 AR - - ü ü Alport syndrome, COL4A5-related COL4A5 XL - - ü ü Alstrom syndrome ALMS1 AR - - ü ü Anauxetic dysplasia; Cartilage-hair hypoplasia; RMRP AR ü ü Metaphyseal dysplasia without hypotrichosis - - Andermann syndrome SLC12A6 AR - - ü ü Arginase deficiency ARG1 AR - - ü ü Argininosuccinate lyase deficiency ASL AR - - ü ü Aromatase deficiency CYP19A1 AR - - ü ü Arts syndrome; Rosenberg-Chutorian syndrome; Phosphoribosylpyrophosphate synthetase PRPS1 XL ü ü superactivity; Non-syndromic hearing loss, - - PRPS1-related Asparagine synthetase deficiency ASNS AR - - ü ü Aspartylglucosaminuria AGA AR - - ü ü Ataxia with isolated vitamin E deficiency TTPA AR - - ü ü Ataxia-telangiectasia ATM AR - - ü ü Autoimmune polyendocrinopathy syndrome type I AIRE AR - - ü ü Autosomal Recessive Spastic Ataxia of SACS AR ü ü Charlevoix-Saguenay - - Bardet-Biedl syndrome 14; Joubert syndrome 5; Leber congenital amaurosis 10; Meckel syndrome CEP290 AR - - ü ü 4; Senior-Løken syndrome 6 Bardet-Biedl syndrome type 1 BBS1 AR - - ü ü Bardet-Biedl syndrome type 10 BBS10 AR - - ü ü Bardet-Biedl syndrome type 12 BBS12 AR - - ü ü Bare lymphocyte syndrome, type II CIITA AR - - ü ü Bartter syndrome BSND AR - - ü ü Bernard-Soulier syndrome type A1 GP1BA AR - - ü ü Bernard-Soulier syndrome type C GP9 AR - - ü ü Bilateral frontoparietal polymicrogyria ADGRG1 AR - - ü ü Biotinidase deficiency BTD AR - - ü ü Björnstad syndrome; GRACILE syndrome; BCS1L AR ü ü Mitochondrial complex III deficiency - - Carbamoylphosphate synthetase I deficiency CPS1 AR - - ü ü Carnitine palmitoyltransferase IA deficiency CPT1A AR - - ü ü Carnitine-acylcarnitine translocase deficiency SLC25A20 AR - - ü ü Carpenter syndrome RAB23 AR - - ü ü Cerebrotendinous xanthomatosis CYP27A1 AR - - ü ü Charcot-Marie-Tooth disease, type 4D NDRG1 AR - - ü ü Charcot-Marie-Tooth disease, X-linked type 1 GJB1 XL - - ü ü Chediak-Higashi syndrome LYST AR - - ü ü Chondrodysplasia punctata type 1, X-linked ARSE XL - - ü ü Choreoacanthocytosis VPS13A AR - - ü ü * Turnaround time may vary if specimen requires additional confirmatory testing. Please contact the laboratory for additional details. † This gene count reflects testing for female patients. Male patients will not be screened for X-linked conditions. ‡ Please visit our website for ethnicity-specific analytical detection rates. 4978 Santa Anita Ave, Suite 205, Temple City, CA 91780 | www.FulgentGenetics.com | [email protected] | P +1 626.350.0537 | F +1 626.454.1667 2019 © Fulgent Genetics. All Rights Reserved. D#FLY-Beacon_Genes_Conds_v2 3 ACOG/ Expanded Focus Expanded Condition Gene Inheritance ACMG Plus (30 genes†) (401 genes†) (6 genes†) (410 genes†) Choroideremia CHM XL - - ü ü Chronic granulomatous disease CYBA AR - - ü ü Chronic granulomatous disease, X-linked CYBB XL - - ü ü Citrin deficiency SLC25A13 AR - - ü ü Cockayne syndrome type A ERCC8 AR - - ü ü Cockayne syndrome type B; ERCC6 AR ü ü De Sanctis-Cacchione syndrome - - Cohen syndrome VPS13B AR - - ü ü Combined malonic and methylmalonic aciduria ACSF3 AR - - ü ü Combined oxidative phosphorylation deficiency, GFM1 AR ü ü GFM1-related - - Combined oxidative phosphorylation deficiency, TSFM AR ü ü TSFM-related - - Combined pituitary hormone deficiency 2 PROP1 AR - - ü ü Combined pituitary hormone deficiency 3 LHX3 AR - - ü ü Congenital adrenal hyperplasia due to CYP11B1 AR ü ü 11-beta-hydroxylase deficiency - - Congenital adrenal hyperplasia due to CYP17A1 AR ü ü 17-alpha-hydroxylase deficiency - - Congenital adrenal hyperplasia due to CYP21A2 AR ü ü 21-hydroxylase deficiency - - Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase HSD3B2 AR - - ü ü 2 deficiency Congenital adrenal hypoplasia, X-linked NR0B1 XL - - ü ü Congenital disorder of glycosylation type Ib MPI AR - - ü ü Congenital disorder of glycosylation type Ic ALG6 AR - - ü ü Congenital hyperinsulinism; KCNJ11 AR ü ü Permanent neonatal diabetes mellitus - - Congenital ichthyosis TGM1 AR - - ü ü Congenital insensitivity to pain with anhidrosis NTRK1 AR - - ü ü Congenital myasthenic syndrome, CHRNE AR ü ü CHRNE-related - - Congenital myasthenic syndrome, RAPSN-related; Fetal akinesia RAPSN AR - - ü ü deformation sequence Congenital nephrotic syndrome, type 1 NPHS1 AR - - ü ü Congenital nephrotic syndrome, type 2 NPHS2 AR - - ü ü Congenital secretory chloride diarrhea SLC26A3 AR - - ü ü Corneal endothelial dystrophy SLC4A11 AR - - ü ü Corticosterone methyloxidase deficiency CYP11B2 AR - - ü ü Costeff syndrome OPA3 AR - - ü ü Creatine
Recommended publications
  • The Landscape of Cancer Cell Line Metabolism

    The Landscape of Cancer Cell Line Metabolism

    The Landscape of Cancer Cell Line Metabolism The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Haoxin, Shaoyang Ning, Mahmoud Ghandi, Gregory V. Kryukov, Shuba Gopal, Amy Deik, Amanda Souza, et. al. 2019. The Landscape of Cancer Cell Line Metabolism. Nature Medicine 25, no. 5: 850-860. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41899268 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Med Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 November 08. Published in final edited form as: Nat Med. 2019 May ; 25(5): 850–860. doi:10.1038/s41591-019-0404-8. The Landscape of Cancer Cell Line Metabolism Haoxin Li1,2, Shaoyang Ning3, Mahmoud Ghandi1, Gregory V. Kryukov1, Shuba Gopal1, Amy Deik1, Amanda Souza1, Kerry Pierce1, Paula Keskula1, Desiree Hernandez1, Julie Ann4, Dojna Shkoza4, Verena Apfel5, Yilong Zou1, Francisca Vazquez1, Jordi Barretina4, Raymond A. Pagliarini4, Giorgio G. Galli5, David E. Root1, William C. Hahn1,2, Aviad Tsherniak1, Marios Giannakis1,2, Stuart L. Schreiber1,6, Clary B. Clish1,*, Levi A. Garraway1,2,*, and William R. Sellers1,2,* 1Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA 2Department
  • Educational Paper Ciliopathies

    Educational Paper Ciliopathies

    Eur J Pediatr (2012) 171:1285–1300 DOI 10.1007/s00431-011-1553-z REVIEW Educational paper Ciliopathies Carsten Bergmann Received: 11 June 2011 /Accepted: 3 August 2011 /Published online: 7 September 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Cilia are antenna-like organelles found on the (NPHP) . Ivemark syndrome . Meckel syndrome (MKS) . surface of most cells. They transduce molecular signals Joubert syndrome (JBTS) . Bardet–Biedl syndrome (BBS) . and facilitate interactions between cells and their Alstrom syndrome . Short-rib polydactyly syndromes . environment. Ciliary dysfunction has been shown to Jeune syndrome (ATD) . Ellis-van Crefeld syndrome (EVC) . underlie a broad range of overlapping, clinically and Sensenbrenner syndrome . Primary ciliary dyskinesia genetically heterogeneous phenotypes, collectively (Kartagener syndrome) . von Hippel-Lindau (VHL) . termed ciliopathies. Literally, all organs can be affected. Tuberous sclerosis (TSC) . Oligogenic inheritance . Modifier. Frequent cilia-related manifestations are (poly)cystic Mutational load kidney disease, retinal degeneration, situs inversus, cardiac defects, polydactyly, other skeletal abnormalities, and defects of the central and peripheral nervous Introduction system, occurring either isolated or as part of syn- dromes. Characterization of ciliopathies and the decisive Defective cellular organelles such as mitochondria, perox- role of primary cilia in signal transduction and cell isomes, and lysosomes are well-known
  • Ciliopathiesneuromuscularciliopathies Disorders Disorders Ciliopathiesciliopathies

    Ciliopathiesneuromuscularciliopathies Disorders Disorders Ciliopathiesciliopathies

    NeuromuscularCiliopathiesNeuromuscularCiliopathies Disorders Disorders CiliopathiesCiliopathies AboutAbout EGL EGL Genet Geneticsics EGLEGL Genetics Genetics specializes specializes in ingenetic genetic diagnostic diagnostic testing, testing, with with ne nearlyarly 50 50 years years of of clinical clinical experience experience and and board-certified board-certified labor laboratoryatory directorsdirectors and and genetic genetic counselors counselors reporting reporting out out cases. cases. EGL EGL Genet Geneticsics offers offers a combineda combined 1000 1000 molecular molecular genetics, genetics, biochemical biochemical genetics,genetics, and and cytogenetics cytogenetics tests tests under under one one roof roof and and custom custom test testinging for for all all medically medically relevant relevant genes, genes, for for domestic domestic andand international international clients. clients. EquallyEqually important important to to improving improving patient patient care care through through quality quality genetic genetic testing testing is is the the contribution contribution EGL EGL Genetics Genetics makes makes back back to to thethe scientific scientific and and medical medical communities. communities. EGL EGL Genetics Genetics is is one one of of only only a afew few clinical clinical diagnostic diagnostic laboratories laboratories to to openly openly share share data data withwith the the NCBI NCBI freely freely available available public public database database ClinVar ClinVar (>35,000 (>35,000 variants variants on on >1700 >1700 genes) genes) and and is isalso also the the only only laboratory laboratory with with a a frefree oen olinnlein dea dtabtaabsaes (eE m(EVmCVlaCslas)s,s f)e, afetuatruinrgin ag vaa vraiarniatn ctl acslasisfiscifiactiaotino sne saercahrc ahn adn rde rpeoprot rrte rqeuqeuset sint tinetrefarcfaec, ew, hwichhic fha cfailcitialiteatse rsa praidp id interactiveinteractive curation curation and and reporting reporting of of variants.
  • The Inherited Metabolic Disorders News

    The Inherited Metabolic Disorders News

    The Inherited Metabolic Disorders News Summer 2011 Volume 8 Issue 2 From the Editor I hope everyone is enjoying their summer thus far! Our 8th annual Metabolic Family Day and 7th annual Low In this Issue Protein Cooking Demonstration were once again a huge success. See the section ”What’s New” on page 9 for a full report of the events, as well as pictures. ♦ From the Editor…1 As always, your suggestions and stories are welcome. Please contact me by email: [email protected] or telephone 519-685-8453 if you wish to contribute to the ♦ From Dr. Chitra Prasad…1 newsletter. I hope everyone has a safe and happy summer! ♦ Personal Stories… 2 Janice Little ♦ Featured This Issue … 4 From Dr Chitra Prasad ♦ Suzanne’s Corner… 6 Dear Friends, ♦ What’s New… 8 Hope you all are having a wonderful summer. We had a great metabolic family workshop with around 198 registrants this year. This was truly phenomenal. Thanks to all the team members and ♦ Research & Presentations … 13 the families in the planning committee for doing such a fantastic job. I was really touched when one of our young metabolic patients told her parents that she would like to attend the ♦ How to Make a Donation… 14 metabolic family workshop! Please see some of the highlights of the metabolic workshop in the newsletter for those who could not make it. The speeches by our youth (Sadiq, Leanna and Laura) ♦ Contact Information … 15 were appreciated by everyone. Big thanks to Jill Tosswill (our previous social worker) who coordinated their talks.
  • Supplement 1 Overview of Dystonia Genes

    Supplement 1 Overview of Dystonia Genes

    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
  • An Overview of Lesch-Nyhan Syndrome

    An Overview of Lesch-Nyhan Syndrome

    An Overview of Lesch-Nyhan Syndrome Abstract Lesch-Nyhan Syndrome is a disorder that strikes the sufferer with debilitating motor and cognitive problems, hyperuricemia, and the urge to do harm to yourself with acts of self-injurious behavior. Research has lead to the discovery of a genetic sequence that results in a defective enzyme, but researchers are still unsure how this leads to the neurological and behavioral problems that are the hallmark of the disorder. Treatments as simple as wearing oven mitts and as complicated as electrical wiring in the brain have been used to help LNS patients, but no cure for the syndrome seems in sight. Lars Sorensen Prof. Stanley Vitello : IDD : 293:522 : Fall 2008 Rutgers University - Graduate School of Education Introduction In the world of developmental and physical disorders none is stranger than Lesch-Nyhan Syndrome. It brings with it a variety of physical ailments but the defining feature of the condition is behavioral. The sufferer seems to be overtaken with an involuntary uncontrollable compulsion to destroy themselves and those around them. In the autumn of 1962, a young mother brought her four year old son to the pediatric emergency room at Johns Hopkins medical center. The boy had previously been diagnosed with cerebral palsy and could not walk or sit up. He was experiencing pain when he urinated. His mother told the resident who was examining the boy that he had “sand in his diaper” (Preston, 2007). The young boy was admitted to the hospital. The resident and an intern began examining the “sand” from the boy's diaper.
  • Mutation of the Fumarase Gene in Two Siblings with Progressive Encephalopathy and Fumarase Deficiency T

    Mutation of the Fumarase Gene in Two Siblings with Progressive Encephalopathy and Fumarase Deficiency T

    Mutation of the Fumarase Gene in Two Siblings with Progressive Encephalopathy and Fumarase Deficiency T. Bourgeron,* D. Chretien,* J. Poggi-Bach, S. Doonan,' D. Rabier,* P. Letouze,I A. Munnich,* A. R6tig,* P. Landneu,* and P. Rustin* *Unite de Recherches sur les Handicaps Genetiques de l'Enfant, INSERM U393, Departement de Pediatrie et Departement de Biochimie, H6pital des Enfants-Malades, 149, rue de Sevres, 75743 Paris Cedex 15, France; tDepartement de Pediatrie, Service de Neurologie et Laboratoire de Biochimie, Hopital du Kremlin-Bicetre, France; IFaculty ofScience, University ofEast-London, UK; and IService de Pediatrie, Hopital de Dreux, France Abstract chondrial enzyme (7). Human tissue fumarase is almost We report an inborn error of the tricarboxylic acid cycle, fu- equally distributed between the mitochondria, where the en- marase deficiency, in two siblings born to first cousin parents. zyme catalyzes the reversible hydration of fumarate to malate They presented with progressive encephalopathy, dystonia, as a part ofthe tricarboxylic acid cycle, and the cytosol, where it leucopenia, and neutropenia. Elevation oflactate in the cerebro- is involved in the metabolism of the fumarate released by the spinal fluid and high fumarate excretion in the urine led us to urea cycle. The two isoenzymes have quite homologous struc- investigate the activities of the respiratory chain and of the tures. In rat liver, they differ only by the acetylation of the Krebs cycle, and to finally identify fumarase deficiency in these NH2-terminal amino acid of the cytosolic form (8). In all spe- two children. The deficiency was profound and present in all cies investigated so far, the two isoenzymes have been found to tissues investigated, affecting the cytosolic and the mitochon- be encoded by a single gene (9,10).
  • (Hunter Syndrome) Complicated by Autoimmune Hemolytic Anemia

    (Hunter Syndrome) Complicated by Autoimmune Hemolytic Anemia

    Bone Marrow Transplantation (2000) 25, 1093–1099 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt Case report Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia CA Mullen1,2, JN Thompson3, LA Richard and KW Chan1 Departments of 1Pediatrics and 2Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas; 3Laboratory of Medical Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA Summary: a median of 21 years in type IIB.8 Allogeneic BMT has been used to treat Hunter disease, but remains controversial This report describes unrelated umbilical cord blood since it often fails to reverse CNS impairment9–11 and car- transplantation for a 10-month-old infant boy with ries with it substantial early mortality and morbidity. Here, mucopolysaccharidosis IIB (Hunter syndrome), an X- we report treatment of an infant with mucopolysacch- linked metabolic storage disorder due to deficiency of arisosis type IIB with transplantation of unrelated umbilical iduronate sulfatase. Two years after transplant ෂ55% cord blood cells and its complication by autoimmune hemo- normal plasma enzyme activity has been restored and lytic anemia. abnormal urinary excretion of glycosaminoglycans has nearly completely resolved. The boy has exhibited nor- mal growth and development after transplant. Nine Case report months after transplant he developed severe auto- immune hemolytic anemia and required 14 months of The patient is the only child of a couple with a maternal corticosteroid treatment to prevent clinically significant family history of Hunter syndrome. The mother’s brother anemia. Bone marrow transplantation for Hunter syn- was diagnosed with Hunter syndrome in 1979 at age 3 years drome and post-transplant hemolytic anemia are when he exhibited the physical stigmata of the disorder.
  • The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
  • Menkes Disease in 5 Siblings

    Menkes Disease in 5 Siblings

    Cu(e) the balancing act: Copper homeostasis explored in 5 siblings Poster with variable clinical course 595 Sonia A Varghese MD MPH MBA and Yael Shiloh-Malawsky MD Objective Methods Case Presentation Discussion v Present a unique variation of v Review literature describing v The graph below depicts the phenotypic spectrum seen in the 5 brothers v ATP7A mutations produce a clinical spectrum phenotype and course in siblings copper transport disorders v Mom is a known carrier of ATP7A mutation v Siblings 1, 2, and 5 follow a more classic with Menkes Disease (MD) v Apply findings to our case of five v There is limited information on the siblings who were not seen at UNC Menke’s course, while siblings 3 and 4 exhibit affected siblings v The 6th sibling is the youngest and is a healthy female infant (not included here) a phenotypic variation Sibling: v This variation is suggestive of a milder form of Background Treatment birth Presentation Exam Diagnostic testing Outcomes Copper Histidine Menkes such as occipital horn syndrome with v Mutations in ATP7A: copper deficiency order D: 16mos residual copper transport function (Menkes disease) O/AD: 1 Infancy/12mos N/A N/A No Brain v Siblings 3 and 4 had improvement with copper v Mutations in ATP7B: copper overload FTT, Seizures, DD hemorrhage supplementation, however declined when off (Wilson disease) O/AD: Infancy/NA D: 13mos supplementation -suggesting residual ATP7A v The amount of residual functioning 2 N/A N/A No FTT, FTT copper transport function copper transport influences disease Meningitis
  • Abstracts from the 9Th Biennial Scientific Meeting of The

    Abstracts from the 9Th Biennial Scientific Meeting of The

    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
  • Disease Reference Book

    Disease Reference Book

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................